Netherlands' Argenx Q4 sales rise 90%, posts first profitable year

argenx SE

26/02/2026 06:14

Overview

Netherlands immunology firm's Q4 global product sales grew 90% yr/yr

Company achieved $1.1 bln in operating income in 2025, marking first year of profitability

Company expands VYVGART label with positive ADAPT OCULUS study results

Outlook

Argenx expects topline results for primary ITP in Q4 2026

Company plans to launch VYVGART SC autoinjector in 2027

Argenx anticipates registrational study in Graves’ disease to start in 2026

Result Drivers

VYVGART SALES GROWTH - Argenx reported a 90% year-over-year increase in global product net sales, driven by VYVGART's expansion and adoption

PIPELINE ADVANCEMENT - The company advanced its pipeline with positive results from the ADAPT OCULUS study and ongoing studies in multiple indications

STRATEGIC EXPANSION - Argenx's strategic focus on expanding its FcRn portfolio and developing new pipeline candidates supports its Vision 2030 growth plan

Company press release: ID:nGNX8NTGsK

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
$8.02
Q4 Net Income
$532.95 mln
Q4 Basic EPS
$8.63
Q4 Operating Expenses
-$954.54 mln
Q4 Total Operating Income
$1.32 bln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for argenx SE is €858.00, about 20.8% above its February 25 closing price of €710.20

The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 32 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)